Evaluation of Antibody Properties and Clinically Relevant Immunogenicity, Anaphylaxis, and Hypersensitivity Reactions in Two Phase III Trials of Tralokinumab in Severe, Uncontrolled Asthma

INTRODUCTION: Tralokinumab is a monoclonal antibody (mAb) that neutralizes interleukin (IL)-13, a cytokine involved in the pathogenesis of asthma. OBJECTIVE: The objectives of this study were to characterize the potential immunogenic properties of tralokinumab and report data for anti-drug antibodie...

Descripción completa

Detalles Bibliográficos
Autores principales: Carlsson, Mats, Braddock, Martin, Li, Yuling, Wang, Jihong, Xu, Weichen, White, Nicholas, Megally, Ayman, Hunter, Gillian, Colice, Gene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6520328/
https://www.ncbi.nlm.nih.gov/pubmed/30649752
http://dx.doi.org/10.1007/s40264-018-00788-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6520328/
https://www.ncbi.nlm.nih.gov/pubmed/30649752
http://dx.doi.org/10.1007/s40264-018-00788-w

Ejemplares similares